ОСОБЕННОСТИ КОНТРАЦЕПЦИИ У ЖЕНЩИН ПОЗДНЕГО РЕПРОДУКТИВНОГО ВОЗРАСТА


Артымук Н.В., Тачкова О.А., Марочко Т.Ю.

Аннотация


Цель исследования – провести аналитический обзор современных источников научной литературы, освещающих особенности контрацепции у женщин позднего репродуктивного возраста.

Материалы и методы. Проведен анализ 43 зарубежных и отечественных источников литературы по данной теме.

Результаты. Несмотря на снижение фертильности, женщины в период менопаузального перехода нуждаются в контрацепции. Методами выбора являются внутриматочная и гормональная контрацепция, а также хирургическая стерилизация. После 50 лет гормональная контрацепция может включать только прогестагенсодержащие препараты, для предупреждения потери костной ткани следует воздержаться от применения ДМПА. Методы контрацепции могут иметь лечебные неконтрацептивные эффекты, однако их назначение следует проводить с учетом состояния здоровья и возможных факторов риска. Поскольку риск беременности становится крайне низким, когда женщина достигает 55 лет, контрацепция может быть прекращена в этом возрасте даже у менструирующих женщин.

Заключение. Контрацепция в позднем репродуктивном возрасте имеет существенные особенности и должна рекомендоваться с учетом имеющихся факторов риска.


Ключевые слова


контрацепция; период менопаузального перехода; перименопауза; поздний репродуктивный возраст

Полный текст:

Full Text PDF Full Text HTML

Литература


U.S. Preventive Services Task Force. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement (Draft). Available at: http://www.uspreventiveservicestaskforce.org/draftrec.htm. Accessed June 7, 2012

Harlow SD, Gass M, Hall JE et al. Executive summary of the Stages of Reproductive Aging Workshop+10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012; 15: 105-114. http://gynendo.ru/wpcontent/uploads/2012/08/etapi_starenija_reproduct_sist_zhenschin_straw+10.pdf

Artymuk NV, Belokrinitskaya TE. Clinical norms. Obstetrics and gynecology. 2nd ed., revised and enlarged. M.: GEOTAR-Media, 2019. 272 p. Russian (Артымук Н.В. Белокриницкая Т.Е. Клинические нормы. Акушерство и гинекология. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2019. 272 с.)

Artymuk NV, Belokrinitskaya TE. Clinical norms. Obstetrics and gynecology. M.: GEOTAR-Media, 2018. 352 p. (Артымук Н.В., Белокриницкая Т.Е. Клинические нормы. Акушерство и гинекология. М.: ГЭОТАР-Медиа, 2018. 352 с.) https://www.rosmedlib.ru/book/ISBN9785970446546.html

National Institute for Health and Clinical Excellence. Menopause: Diagnosis and Management (NG23) 2015. Last updated 5 December 2019. https://www.nice.org.uk/guidance/ng23/resources/menopause-diagnosis-and-management-pdf-1837330217413

Hardman SMR, Gebbie AE. The contraception needs of the perimenopausal woman. Best Pract Res Clin Obstet Gynaecol. 2014; 28: 903-915

Santoro N, Crawford SL, El Khoudary SR et al. Menstrual cycle hormone changes in women traversing the menopause: study of women’s health across the nation. J Clin Endocrinol Metab. 2017; 22 March (Epub ahead of print). doi:10.1210/jc.2016-4017

Speroff L. The perimenopause: definitions, demography, and physiology. Obstet Gynecol Clin North Am. 2002; 29: 397-410

Vaninetti S, Baccarelli A, Romoli R et al. Effect of aging on serum gonadotropin levels in healthy subjects and patients with nonfunctioning pituitary adenomas. Eur J Endocrinol. 2000; 142: 144-149

Baldwin MK, Jensen JT. Contraception during the perimenopause. Maturitas. 2013; 76: 235-242

Klein J, Sauer MV. Assessing fertility in women of advanced reproductive age. Am J Obstet Gynecol. 2001; 185: 758-770

Nelson SM, Telfer EE, Anderson RA. The ageing ovary and uterus: new biological insights. Hum Reprod Update. 2013; 19: 67-83

Reproductive Endocrinology and Infertility Committee, Family Physicians Advisory Committee, Maternal-Fetal Medicine Committee, et al. Advanced reproductive age and fertility. J Obstet Gynaecol Can. 2011; 33: 1165-1175

Office for National Statistics. Conception Statistics, England and Wales, 2015. 2017. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/conceptionandfertilityrates/datasets/conceptionstatisticsenglandandwalesreferencetables

Faculty of Sexual & Reproductive Healthcare. FSRH Guideline: Contraception for Women Aged Over 40 Years. August 2017 (Amended September 2019) https://www.fsrh.org/standards-and-guidance/documents/fsrh-guidance-contraception-for-women-aged-over-40-years-2017/

Office for National Statistics. Opinions Survey Report No. 41: Contraception and Sexual Health, 2008/09. 2009. http://webarchive.nationalarchives.gov.uk/20160105160709/http://ons.gov.uk/ons/ rel/lifestyles/contraception-and-sexual-health/2008-09/index.html

Dratva J, Gómez Real F, Schindler C et al. Is age at menopause increasing across Europe? Results on age at menopause and determinants from two population-based studies. Menopause N Y N. 2009; 16: 385-394

Bayer Plc. Summary of Product Characteristics: Jaydess 13.5 mg intrauterine delivery system. 2016. https://www.medicines.org.uk/emc/medicine/28672

Royal College of Obstetricians and Gynaecologists (RCOG), British Society for Gynaecological Endoscopy. Management of Endometrial Hyperplasia (Green-top Guideline No. 67). 2016. https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_ endometrial_hyperplasia.pdf

Tepper NK, Whiteman MK, Marchbanks PA et al. Progestin-only contraception and thromboembolism: a systematic review. Contraception. 2016; 94: 678-700

Faculty of Sexual & Reproductive Healthcare (FSRH). Progestogen-only Injectable Contraception. 2014. http://www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-injectables-dec-2014/

Faculty of Sexual & Reproductive Healthcare (FSRH). Progestogen-only Implants. 2014. http://www.fsrh.org/documents/cec-ceu-guidance-implants-feb-2014/

Bahamondes L, Valeria Bahamondes M, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update. 2015; 21: 640-651

Varma R, Mascarenhas L. Endometrial effects of etonogestrel (Implanon) contraceptive implant. Curr Opin Obstet Gynecol. 2001; 13: 335-341

Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis – a pilot study. Contraception. 2009; 79: 29-34

FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, Amended 2019)

Roach REJ, Helmerhorst FM, Lijfering WM et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015; 8: CD011054

Peragallo Urrutia R, Coeytaux RR, McBroom AJ et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol. 2013; 122: 380-389

Lidegaard Ø, Løkkegaard E, Jensen A et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012; 366: 2257-2266

Poulter N, Chang C, Meirik O et al. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996; 348: 505-510

Yang L, Kuper H, Sandin S et al. Reproductive history, oral contraceptive use, and the risk of ischemic and hemorrhagic stroke in a cohort study of middle-aged Swedish women. Stroke. 2009; 40: 1050-1058

Weill A, Dalichampt M, Raguideau F et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016; 353: i2002

Dinger J, Möhner S, Heinemann K. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives. Contraception. 2016; 93: 378-385

Baillargeon J-P, McClish DK, Essah PA et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab. 2005; 90: 3863-3870

Lopez LM, Grimes DA, Gallo MF et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013; 4: CD003552

Nelson HD, Zakher B, Cantor A et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012; 156: 635-648

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet. 1996; 347: 1713-1727

Baber RJ, Panay N, Fenton A, and the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2). DOI: 10.3109/13697137.2015.1129166

Zhu H, Lei X, Feng J et al. Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies. Eur J Contracept Reprod Health Care. 2012; 17: 402-414

Poosari A, Promthet S, Kamsa-ard S et al. Hormonal contraceptive use and breast cancer in Thai women. J Epidemiol Community Health. 2014; 24: 216-220

Gierisch JM, Coeytaux RR, Urrutia RP et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1931-1943

Vessey M, Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception. 2013; 88: 678-683

Gebbie AE, Glasier A, Sweeting V. Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Contraception. 1995; 52: 221-222


Статистика просмотров

Загрузка метрик ...

Ссылки

  • На текущий момент ссылки отсутствуют.